<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029596</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2018-0340</org_study_id>
    <nct_id>NCT05029596</nct_id>
  </id_info>
  <brief_title>Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines</brief_title>
  <official_title>Comparative Effectiveness of Heparin Versus Normal Saline in Maintaining Patency of Peripherally Inserted Central Catheter Lines in Oncology Inpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team will be performing a study comparing the use of Heparin Flushes vs. Normal&#xD;
      Saline Flushes in making sure central lines stay open. The participants will be placed in a&#xD;
      group to receive the University of Texas Southwestern Medical Center (UTSW) Standard of Care&#xD;
      (control group) for maintaining central lines, or a group to receive Normal Saline Flushes&#xD;
      only (experimental group) to keep their central line open. The participants electronic&#xD;
      medical record will be reviewed by study team members for the inclusion/exclusion criteria,&#xD;
      the participants central line will be assessed by an 11 Blue BMT nurse every 12 hours, and&#xD;
      they may be asked questions regarding their medical history during their stay on 11 Blue BMT.&#xD;
      If a participant is discharged or transferred off of the 11 Blue BMT unit, they will no&#xD;
      longer be included in the study and their central line maintenance will return to the UTSW&#xD;
      Standard of Care. Participants in this study may be at risk for central line occlusion (a&#xD;
      blood clot) which could require intervention to regain the free flow of fluids and use of the&#xD;
      central line. The study team predicts there will be no increase in the rate of line occlusion&#xD;
      when using Normal Saline Flushes only to maintain the free flow of fluids through&#xD;
      participants central line. The study team also hopes the results of this study will help to&#xD;
      improve patient outcomes by decreasing risk of infection, heparin associated complications,&#xD;
      and costs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patency</measure>
    <time_frame>Up to Day 7 of enrollment</time_frame>
    <description>To determine whether or not flushing central lines with normal saline only will maintain free flow through these central lines.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection Rate</measure>
    <time_frame>From Day 1 and up to Day 7 of enrollment</time_frame>
    <description>To determine whether or not removing Heparin Flushes from PICC line maintenance decreases the risk for central line associated infections</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Heparin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the UTSW standard of of care for PICC line maintenance.&#xD;
All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive only Normal Saline for PICC line maintenance. All lumens of PICC line will be flushed every 24 hours with 10cc Normal Saline. PICC line will be flushed with 10cc Normal Saline after administration of medication, blood products, or blood draws.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Group</intervention_name>
    <description>A 10cc NS flush will be administered intravenously through the peripherally inserted central line catheter after administration of medication, blood products, and blood draws. In addition the peripherally inserted central line catheter will be flushed intravenously with 10cc Normal Saline every 24 hours.</description>
    <arm_group_label>Normal Saline Group</arm_group_label>
    <other_name>NS Flush, Normal Saline Flush, 0.9% Normal Saline Flush</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Group</intervention_name>
    <description>All lumens of PICC line will be flushed w/ Heparin Flush every 8 hours. PICC line will be flushed with 10cc Normal Saline followed by 3cc Heparin Flush after administration of medication, blood products, or blood draws.</description>
    <arm_group_label>Heparin Group</arm_group_label>
    <other_name>Heparin Flush</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oncology patients&#xD;
&#xD;
          -  Admitted to 11Blue Bone Marrow Transplant Unit at Clements University Hospital&#xD;
             University of Texas Southwestern Medical Center&#xD;
&#xD;
          -  Ages 18-80 years&#xD;
&#xD;
          -  Pre-existing or newly placed PICC line&#xD;
&#xD;
          -  PICC line with good blood return (defined as: &quot;brisk blood return of 3cc&quot;)&#xD;
&#xD;
          -  Flushes without difficulty&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient less than 18 years of age or greater than 80 years of age&#xD;
&#xD;
          -  Refused or unable to give consent to the study&#xD;
&#xD;
          -  Patient admitted to the 11Blue BMT unit with any line other than a PICC line, or&#xD;
             multiple lines&#xD;
&#xD;
          -  Patient admitted to 11Blue BMT for active transplant&#xD;
&#xD;
          -  Patient with a coagulopathy diagnosis&#xD;
&#xD;
          -  Patient on therapeutic dose of anticoagulants for documented Deep Vein Thrombosis or&#xD;
             Pulmonary Embolism&#xD;
&#xD;
          -  Patient on inpatient hospice/comfort care&#xD;
&#xD;
          -  Patient transferred off 11B BMT unit onto another floor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meredith C Allen, BSN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresa Phan</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda Denke</last_name>
    <role>Study Director</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kavitha Nair</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miriam Gonzales</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramona Warkola</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jancy Wilson</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meredith C Allen</last_name>
    <phone>(817) 988-9905</phone>
    <email>meredith.allen@utsouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clements University Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith C Allen, RN</last_name>
      <phone>214-633-1100</phone>
      <email>meredith.allen@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Linda Denke</last_name>
      <phone>214-648-1810</phone>
      <email>linda.denke@utsouthwestern.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Meredith Allen</investigator_full_name>
    <investigator_title>Registered Nurse</investigator_title>
  </responsible_party>
  <keyword>Peripherally Inserted Central Lines</keyword>
  <keyword>Heparin Flush</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

